secwatch.observer — SEC 8-K summary
======================================

Issuer:     ATOSSA THERAPEUTICS, INC. (ATOS)
CIK:        0001488039
Form:       8-K
Filed at:   2026-05-08T23:59:59+00:00
Accession:  0001193125-26-213439
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Operating expenses $9.9M, up 34% YoY; FDA grants RPD for (Z)-endoxifen in DMD and McCune-Albright
--------------------------------------------------------------------------------

- Total operating expenses $9.9M in Q1 2026, up from $7.4M in Q1 2025, driven by higher legal fees for patent litigation (subsequently settled) and R&D costs.
- R&D expenses $4.8M (+15% YoY) on increased clinical trial costs for (Z)-endoxifen; G&A $5.1M (+56%) due to $1.8M in patent litigation legal fees.
- FDA granted Orphan Drug Designation (Jan 2026) and Rare Pediatric Disease designation for (Z)-endoxifen in Duchenne Muscular Dystrophy.
- FDA granted Rare Pediatric Disease designation for (Z)-endoxifen in McCune-Albright Syndrome (May 2026), eligible for Priority Review Voucher (sold for $100-205M).
- Atossa strengthened leadership with two new Medical Directors: Dr. Puyana Theall (Breast Oncology) and Dr. Giwa (Rare Diseases).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1488039/000119312526213439/0001193125-26-213439-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1488039/000119312526213439/atos-20260508.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-213439

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer